In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulse Biosciences Inc.

www.pulsebiosciences.com

Latest From Pulse Biosciences Inc.

Asia Executives On The Move: Merck, Novo Nordisk, Ascentage

Merck China R&D head leaving after overseeing several high-profile drug approvals, while Novo Nordisk China's marketing head will lead the firm's operations in Oceania.
Appointments Asia Pacific

Pulse Biosciences' Shoots For US Clearance Of Nano-Pulse Platform

Pulse Biosciences' nano-pulse technology, PulseTx, precisely targets and kills cells with short electrical pulses that induce cell death and induce an immunogenic response. The company has submitted a 510(k) application to the US FDA for the technology, seeking a broad soft-tissue ablation indication, but it is developing PulseTx for immunoncology and dermatology indication.

Cancer ImmunoOncology

Device/Diagnostics Quarterly Deal Statistics, Q2 2016

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

Deals Market Intelligence

Q2 Breathes A Little Life Into Medtech IPO Scene

After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.

Commercial Companies
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Alias(es)
  • Electroblate Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pulse Biosciences Inc.
  • Senior Management
  • Darrin R Uecker, Pres. & CEO
    Brian B Dow, SVP, CFO
    Richard Nuccitelli, PhD, CSO
    Holly Hartman, PhD, VP, Bus. Dev. & Corp. Strategy
    William Knape, VP, Reg., Clinical & Quality Affairs
    Edison Manuel, VP, Operations
  • Contact Info
  • Pulse Biosciences Inc.
    Phone: (510) 906-4600
    3957 Point Eden Way
    Ste. 104
    Hayward, CA 94545
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register